AurimMed Pharma
AurimMed Pharma is an applied-science, development-stage pharmaceutical company focused on developing innovative drug products for various CNS disease states. Utilizing a proprietary knowledge-base called the Privileged Structure Platform (PSP), the company designs novel compounds with potential for decreased toxicity and increased success in regulatory approval. Their portfolio includes compounds active in CNS disorders such as epilepsy, neuropathic pain, and neuroprotection, with plans to advance through clinical trials and seek partnerships for commercialization.
Industries
Nr. of Employees
small (1-50)
AurimMed Pharma
Patents
Compounds advantageous in the treatment of central nervous system diseases and disorders
US-10793515-B2
View DetailsCompounds advantageous in the treatment of central nervous system diseases and disorders
US-9212155-B2
View DetailsCompounds advantageous in the treatment of central nervous system diseases and disorders
US-9206143-B2
View Details
Compounds advantageous in the treatment of central nervous system diseases and disorders
US-10793515-B2
View DetailsCompounds advantageous in the treatment of central nervous system diseases and disorders
US-9212155-B2
View DetailsCompounds advantageous in the treatment of central nervous system diseases and disorders
US-9206143-B2
View DetailsProducts
Lead CNS-active anticonvulsant development candidate (preclinical/early clinical development)
A small-molecule CNS-active development candidate selected via scaffold-based design showing efficacy in seizure models (including nerve-agent-induced seizures), analgesic activity in pain models, and neuroprotective effects in Parkinson’s disease models; progressed through advanced preclinical testing and positioned for Phase I development.
Lead CNS-active anticonvulsant development candidate (preclinical/early clinical development)
A small-molecule CNS-active development candidate selected via scaffold-based design showing efficacy in seizure models (including nerve-agent-induced seizures), analgesic activity in pain models, and neuroprotective effects in Parkinson’s disease models; progressed through advanced preclinical testing and positioned for Phase I development.
Services
Partnerships with government screening programs, academic laboratories and external screening vendors to advance preclinical evaluation of CNS-active small molecules.
Partnerships with government screening programs, academic laboratories and external screening vendors to advance preclinical evaluation of CNS-active small molecules.
Expertise Areas
- Medicinal chemistry and scaffold-based small-molecule discovery
- Preclinical CNS pharmacology and neuropharmacology
- ADMET-guided lead optimization
- Nonclinical safety and toxicology screening
Key Technologies
- Privileged-scaffold (scaffold-based) drug design
- ADMET-informed lead optimization
- In vivo seizure and neurodegeneration models
- In vitro oxidative-stress and neuroprotection assays
News & Updates
Various updates and achievements including patents, research results, and collaborations.
Official statements and news releases from AurimMed.
In October 2016, patent offices of Singapore and South Korea issued patents for AurimMed CNS-active compounds.
In December 2015, the USPTO issued a patent for AurimMed CNS-active compounds.
In November 2015, Mexico issued a patent for AurimMed CNS-active compounds.
AurimMed Pharma received this award on July 15, 2013.
Various updates and achievements including patents, research results, and collaborations.
Official statements and news releases from AurimMed.
In October 2016, patent offices of Singapore and South Korea issued patents for AurimMed CNS-active compounds.
In December 2015, the USPTO issued a patent for AurimMed CNS-active compounds.
In November 2015, Mexico issued a patent for AurimMed CNS-active compounds.
AurimMed Pharma received this award on July 15, 2013.